Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2019-10-10 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science provides update on masitinib programs timelines
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science providing an update on the timelines for their clinical trial programs (masitinib). It is a corporate announcement regarding operational progress rather than a formal financial report, audit, or regulatory filing. Since it is a general corporate announcement that does not fit into specific categories like M&A or dividend notices, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general corporate announcements.
2019-10-10 English
AB Science communique une mise à jour sur le calendrier des résultats cliniques
Report Publication Announcement Classification · 1% confidence The document is a press release dated October 10, 2019, from AB Science, titled "AB Science communique une mise à jour sur le calendrier des résultats cliniques" (AB Science communicates an update on the clinical results timeline). It details expected timelines for clinical trial readouts (Asthma, Multiple Sclerosis, Alzheimer's, etc.) for Q4 2019, Q2 2020, and 2020. This is an announcement updating investors on future events and timelines, not the release of the actual financial results (ER) or a comprehensive report (IR/10-K). It is a general corporate communication updating stakeholders on operational/development progress. Since it is an announcement updating on future events/reports rather than the report itself, and it doesn't fit specific categories like DIV, DIRS, or MANG, it falls best under a general regulatory announcement or a communication related to investor information. Given the context of updating timelines for clinical results, which is crucial for investor valuation, it is a form of investor relations communication. However, looking at the definitions, it is not a standard Earnings Release (ER) or Interim Report (IR). It is an announcement about the timing of future results. This fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but since it's a text announcement updating timelines, RNS serves as the best general regulatory/corporate update category when a more specific one isn't available. It is not a Report Publication Announcement (RPA) because it is announcing a *schedule update*, not the publication of a specific, attached report (though it has an attachment, the core content is the schedule update). Therefore, RNS is the most appropriate fallback for this type of operational/timeline update.
2019-10-10 French
AB Science communique une mise à jour sur le calendrier des résultats cliniques
Report Publication Announcement Classification · 1% confidence The document is a press release dated October 10, 2019, titled "AB Science communique une mise à jour sur le calendrier des résultats cliniques" (AB Science communicates an update on the clinical results timeline). It details expected timelines for announcing clinical trial results (Asthma, Multiple Sclerosis, Alzheimer's, etc.) for Q4 2019 and 2020. This is not a full financial report (10-K or IR), nor is it a transcript (CT) or a formal dividend/share change notice. It is an announcement updating investors on the progress and timing of key operational/development milestones. This fits best under the general category of Investor Presentation (IP) if it were a presentation, but since it is a formal press release announcing future events and providing context, it is most accurately classified as an announcement regarding the publication of future reports/results, which aligns closely with Report Publication Announcement (RPA) or, if it's a general update not tied to a specific report release date, potentially Regulatory Filings (RNS). Given the focus is explicitly on updating the *schedule* of results, RPA is a strong candidate, but since it's a general corporate update about development timelines rather than announcing the immediate release of a specific document, and it's a standard press release format, RNS (Regulatory Filings/General Announcement) is often used for such non-standard updates. However, the content is highly focused on future report publication dates. Comparing RPA (announcement regarding the timing, release, or publication of company reports) and ER (initial announcement of periodical financial results - this is not the results themselves), RPA seems the most fitting for an announcement about *when* results will be published. I will select RPA as it directly relates to the timing of future report publication.
2019-10-10 French
AB Science provides update on masitinib programs timelines
Regulatory Filings Classification · 1% confidence The document is a press release dated October 10, 2019, providing an update on clinical trial timelines for the company's drug masitinib. It details expected read-out dates for various studies (Q4 2019, Q1 2020, 2020). This type of communication, which announces operational updates, clinical progress, and future expectations, is characteristic of an Earnings Release (ER) or a general Investor Relations update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it best fits the 'Earnings Release' category, which covers initial announcements of key operational/financial highlights, even if the primary focus here is clinical timelines rather than quarterly revenue figures. It is a direct communication of results/updates to the market, fitting the ER definition better than the general 'RNS' fallback.
2019-10-10 English
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2019 et présente un point sur ses activités
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for AB Science SA covering the first half (semestre) of 2019. It includes detailed financial statements (income statement, balance sheet, equity changes), management discussion and analysis of operational results, and clinical trial updates. It is not a short announcement or a certification, but the actual interim financial report. Therefore, it fits the definition of an Interim/Quarterly Report (IR). H1 2019
2019-09-30 French
AB Science today reports its revenues for the first half of 2019 and provides an update on its activities.
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2019 (H1 2019) for AB Science SA. It contains detailed consolidated financial statements, including income statements, balance sheet information, analysis of operating expenses, and management's discussion of financial results and future prospects. Since it covers a period shorter than a full fiscal year and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H2 2019
2019-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.